The IMID Forum

Discussing axSpA: Biologic therapy outcomes in axial spondyloarthritis

Join Dr Sofia Ramiro and Professor Atul Deodhar as they discuss the top publications in the world of axSpA. This month, the conversation covered how certolizumab pegol reduces anterior uveitis flares in high-risk axSpA and the effect of secukinumab dose escalation on MRI inflammation and damage in axSpA.

Author Interview: Professor Valentino Paci, April 2026

Join Professor Peter Nash from the Griffith University in Brisbane, and am Professor Valentino Paci, Medical researcher specialized in immune-mediated diseases, with a particular focus on spondyloarthritis. Collaboration and knowledge exchange are integral to his research philosophy, as they discuss his recent paper ‘Does Prior Exposure Affect Retention? A Real‑World, Multicentre Assessment of IL‑17 Inhibitor Cycling in Psoriatic Arthritis?’.

Discussing RA: Updated EULAR recommendations and next-step strategies after TNF inhibitor failure

Join Professor Iain McInnes and Professor Rieke Alten for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, they will review a paper by Smolen et al. provides an update of the EULAR RA management recommendations addressing the most recent insights; and by Narváez et al. developed evidence-informed, profile-based recommendations to guide treatment selection after inadequate response to a first TNFi in RA, combining evidence and expert consensus.

Discussing PsA: Bimekizumab in PsA: Clinical efficacy and updated safety profile

Join Professor Laura Coates and Phillip Mease as they discuss the top publications in the world of PsA. This month, the conversation covered the ‘safety and clinical efficacy of bimekizumab in patients with active PsA who were bDMARD-naïve or TNFi-IR, and the second provided a comprehensive and updated overview of bimekizumab’s safety profile to support clinical decision-making.

Author Interview: Professor Helena Marzo-Ortega, March 2026

Join Professor Peter Nash from the Griffith University in Brisbane, and Professor Helena Marzo-Ortega an academic clinician and the Clinical Lead of the multi-award winning Leeds Specialist Spondyloarthropathy service at The Leeds Teaching Hospitals NHS Trust, as they discuss her recent paper ‘EULAR points to consider and consensus definitions for difficult-to-manage and treatment-refractory psoriatic arthritis’.